NCT07193394

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer: a Proof of Concept Study (H3RAKLES)

ClinicalTrials.gov

Sponsor

Institut Curie

Status

Recruiting

Versions

Adjacent patches

Severity is deterministic, reproducible, uncalibrated triage metadata, not validated review priority or proven wrongdoing. New Evidence Record packages are generated for deterministic event-class membership, not by triage rank alone.

Material event timeline

1 shown

Triage: Medium

2026-01-20

Timeline Shift

v0 to v1 Pre Recruitment Inspect patch

/protocolSection/statusModule/lastUpdatePostDateStruct/date

/protocolSection/statusModule/lastUpdateSubmitDate

/protocolSection/statusModule/startDateStruct/date